1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

REMS For Mavacamten Could Involve Additional Monitoring, BMS Says

User Fee Delayed; Potential For Systolic Dysfunction Needs Watching

 
• By Mandy Jackson

The FDA will take three more months to review mavacamten, a treatment for hypertrophic cardiomyopathy that BMS expects to be one of the company’s next blockbusters. 

Stethoscope And Stress Ball In Heart Shape On Wooden Background
The action date for mavacamten has moved from 28 January to 28 April • Source: Alamy

A delay in the user fee deadline for Bristol Myers Squibb Company’s cardiac drug mavacamten over a proposed risk evaluation and mitigation strategy (REMS) could involve the need for additional monitoring, the company told Scrip. It remains to be seen if the REMS requirements could diminish mavacamten’s profile versus a competitor with a similar mechanism of action.

The 90-day extension of the US Food and Drug Administration review deadline, announced 19 November, shifts the action date for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Stock Watch: Pfizer’s Vyndaqel Withdrawal

 
• By Andy Smith

The removal of a lower-dose version of a drug with years of patent-protected sales remaining in favor of a higher dose, lower-pill count version was billed as a convenience enhancement for patients. Payers, however, do not reimburse convenience.

September Deals Freshen Up Novartis’s Cardio Franchise

 
• By Kevin Grogan

As its biggest seller Entresto succumbs to generic competition.

Novartis Buys Tourmaline Bio, Setting Up Showdown With Novo Nordisk

 
• By Manas Mishra

Novartis is acquiring Tourmaline Bio for $1.4bn to gain pacibekitug, a promising IL-6 inhibitor for cardiovascular disease, setting up a direct rivalry with Novo Nordisk’s ziltivekimab.

Hengrui’s Lucrative Dealmaking Year Continues With Braveheart

 
• By Joseph Haas

Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.

More from Therapy Areas

Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?

 
• By Aakash Babu

With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.

Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP

 
• By Alaric DeArment

The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.